Kymera Therapeutics Inc
KYMR49.130USD
-2.030-3.97%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
3.47BMarket Cap
LossP/E TTM
More Details of Kymera Therapeutics Inc Company
Kymera Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. The Company's targeted protein degradation (TPD) platform, which it refers to as Pegasus, allows it to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. It utilized its Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and it continues to apply its platform’s capabilities to additional therapeutic areas. Its clinical stage programs are IRAK4, STAT3, and MDM2, which each address high impact targets within biologically proven pathways, providing the opportunity to treat a range of immuno-inflammatory diseases, hematologic malignancies, and/or solid tumors.
Company Info
Ticker SymbolKYMR
Company nameKymera Therapeutics Inc
IPO dateAug 21, 2020
CEODr. Nello Mainolfi, Ph.D.
Number of employees188
Security typeOrdinary Share
Fiscal year-endAug 21
Address500 North Beacon Street, 4Th Floor
CityWATERTOWN
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code02472
Phone18572855314
Websitehttps://www.kymeratx.com/
Ticker SymbolKYMR
IPO dateAug 21, 2020
CEODr. Nello Mainolfi, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Nello Mainolfi, Ph.D.
Dr. Nello Mainolfi, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
659.96K
--
Dr. Jared August Gollob, M.D.
Dr. Jared August Gollob, M.D.
Chief Medical Officer
Chief Medical Officer
67.50K
+23.48%
Mr. Brian R. Adams, J.D.
Mr. Brian R. Adams, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
52.50K
--
Mr. Noah Goodman
Mr. Noah Goodman
Chief Business Officer
Chief Business Officer
50.08K
--
Dr. Jeremy G. Chadwick, Ph.D.
Dr. Jeremy G. Chadwick, Ph.D.
Chief Operating Officer
Chief Operating Officer
15.80K
-14.01%
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Ms. Justine Koenigsberg
Ms. Justine Koenigsberg
Vice President - Investor Relations
Vice President - Investor Relations
--
--
Mr. Jeffrey W. (Jeff) Albers, J.D.
Mr. Jeffrey W. (Jeff) Albers, J.D.
Independent Director
Independent Director
--
--
Dr. Bruce L. Booth
Dr. Bruce L. Booth
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
--
--
Dr. Gorjan Hrustanovic, Ph.D.
Dr. Gorjan Hrustanovic, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Nello Mainolfi, Ph.D.
Dr. Nello Mainolfi, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
659.96K
--
Dr. Jared August Gollob, M.D.
Dr. Jared August Gollob, M.D.
Chief Medical Officer
Chief Medical Officer
67.50K
+23.48%
Mr. Brian R. Adams, J.D.
Mr. Brian R. Adams, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
52.50K
--
Mr. Noah Goodman
Mr. Noah Goodman
Chief Business Officer
Chief Business Officer
50.08K
--
Dr. Jeremy G. Chadwick, Ph.D.
Dr. Jeremy G. Chadwick, Ph.D.
Chief Operating Officer
Chief Operating Officer
15.80K
-14.01%
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2024
No Data
By RegionUSD
Name
Revenue
Proportion
United States
47.07M
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Aug 19
Updated: Tue, Aug 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
T. Rowe Price Associates, Inc.
9.51%
Baker Bros. Advisors LP
9.30%
Avoro Capital Advisors LLC
9.17%
The Vanguard Group, Inc.
7.85%
BVF Partners L.P.
7.70%
Other
56.47%
Shareholders
Shareholders
Proportion
T. Rowe Price Associates, Inc.
9.51%
Baker Bros. Advisors LP
9.30%
Avoro Capital Advisors LLC
9.17%
The Vanguard Group, Inc.
7.85%
BVF Partners L.P.
7.70%
Other
56.47%
Shareholder Types
Shareholders
Proportion
Investment Advisor
44.84%
Investment Advisor/Hedge Fund
29.62%
Hedge Fund
25.45%
Venture Capital
7.99%
Individual Investor
1.45%
Corporation
1.08%
Research Firm
0.79%
Private Equity
0.69%
Bank and Trust
0.35%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
394
76.16M
108.56%
+417.04K
2025Q1
408
74.79M
106.76%
-4.90M
2024Q4
392
73.17M
112.73%
-3.17M
2024Q3
379
71.17M
110.57%
-5.78M
2024Q2
360
69.86M
113.52%
-7.55M
2024Q1
364
70.22M
115.13%
-982.70K
2023Q4
350
63.05M
113.62%
-5.46M
2023Q3
341
59.94M
108.11%
-9.64M
2023Q2
349
61.24M
110.72%
-7.83M
2023Q1
353
62.67M
113.41%
-6.15M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
T. Rowe Price Associates, Inc.
6.65M
9.48%
-169.69K
-2.49%
Mar 31, 2025
Baker Bros. Advisors LP
6.65M
9.48%
+655.50K
+10.93%
Jun 30, 2025
Avoro Capital Advisors LLC
6.46M
9.21%
+1.31M
+25.44%
Mar 31, 2025
The Vanguard Group, Inc.
5.22M
7.45%
+344.08K
+7.05%
Mar 31, 2025
BVF Partners L.P.
5.48M
7.81%
+317.17K
+6.14%
Jun 30, 2025
Fidelity Management & Research Company LLC
4.41M
6.28%
-421.36K
-8.72%
Mar 31, 2025
Wellington Management Company, LLP
6.00M
8.55%
+689.55K
+12.99%
Mar 31, 2025
Atlas Venture
4.90M
6.98%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.63M
5.17%
-76.67K
-2.07%
Mar 31, 2025
Invus Public Equities Advisors, LLC
3.24M
4.62%
+270.58K
+9.11%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
